Course InformationTherapautic Area: Neurology
Credit(s): .50 AMA PRA Category 1 Credit(s)™
Activity Dates: December 7, 2017 to December 6, 2018
In this module of a Four-Part Expert Interview Series, Dr. Marc E. Agronin, along with Dr. Richard S. Isaacson, course chair, will evaluate available therapeutic options for Alzheimer’s disease (AD) patient. The faculty will highlight the evolution of failed and existing therapies in AD, and their impact on current clinical care, emphasizing strategies for delaying disease progression in the modern day. Emerging therapies for the treatment and management of Alzheimer’s disease will also be assessed. Through completing this educational activity, learners will be better acquainted with emerging and emerged clinical trial data as it relates to AD care.
Neurologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.
I. Analyze clinical trial data of emerging therapeutics to delay progression in the treatment of AD
II. Implement shared decision making with the multidisciplinary team and patients/caregivers to develop individualized treatment plans and referral to clinical studies to advance treatment and improve the quality of life for patients with AD
Marc E. Agronin, MD
Vice President, Behavioral Health and Clinical Research
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
|Faculty||Relationship Identified With:|
|Marc E. Agronin, MD||Consultant/Advisor: Eli Lilly and CompanySpeaker’s Bureau: Allergan|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of .50 CNE contact hour(s) (.50 CNE pharmacotherapeutic contact hours).
This activity has been supported by an independent educational grant from Biogen.